Researchers at the University of Pennsylvania have developed a novel fungal genome-editing tool, fPE7max, which could unlock new cancer treatments. This breakthrough was detailed in a study published on July 3, 2026, in Nature Biotechnology. The team, led by chemical engineer Xue "Sherry" Gao, aims to manipulate the genetic pathways of filamentous fungi to discover new compounds with anti-cancer properties.
Unlocking Fungal Potential with fPE7max
Fungi have historically been overlooked in genomic studies, despite their significant contributions to medicine, such as penicillin and statins. Gao emphasizes the importance of fungi in drug discovery, stating, "From the serendipitous discovery of penicillin to cholesterol-lowering statins, we owe many recent breakthroughs in longevity to fungal chemistry." The fPE7max tool allows researchers to activate silent gene pathways in fungi, which are typically inactive in sterile lab conditions.
The fPE7max tool operates with impressive efficiency, achieving nearly 90% editing success. It enables the precise manipulation of fungal genomes, particularly targeting the regulatory sequences of master genes like laeA. This approach not only revives dormant gene clusters but also leads to the identification of new compounds, some of which exhibit promising anticancer properties.
Key Findings from the Research
The research team isolated 18 distinct complex molecules, with eight being entirely new to science. Notably, three of these molecules showed early-stage anti-cancer activity. Chunxiao Sun, a postdoctoral researcher in the Gao Lab, stated, "Of these uncovered molecules, three exhibited promising anticancer properties. These molecules can serve as lead compounds for disease treatment, providing a vital new pipeline for drug discovery." One specific molecule demonstrated selective toxicity against human breast, hepatic, and leukemia cancer cells.
